Jiangsu gdk Biotechnology Co., Ltd.SSE: 688670

(688670)"JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD."Announcement on Risk Warning Regarding the Receipt of a Drug Registration Certificate for the Company's Split Virion Influenza Vaccine and Uncertainty in Operating Performance

· Issued by Jiangsu gdk Biotechnology Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688670 · · 3 pages · Chinese

Summary by 6ix AI

Jiangsu gdk Biotechnology Co., Ltd. announced the receipt of a drug registration certificate for its split virion influenza vaccine, highlighting its significance in the company's product lineup. The company warns of uncertainties in its operating performance due to factors such as market competition and the timing of product sales. It notes that the sales of the new vaccine may be limited this season, impacting overall revenue and potentially leading to financial risks.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/688670jiangsu-gdk-biological-technology-co-ltdannouncement-on-risk-warning-regarding-the-receipt-of-a-drug-registration-certificate-for-the-companys-split-virion-influenza-vaccine-and-uncertainty-in-operating-performance

Release

Announcement on Risk Warning Regarding the Receipt of a Drug Registration Certificate for the Company's Split Virion Influenza Vaccine and Uncertainty in Operating Performance

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Jiangsu gdk Biotechnology Co., Ltd. on 6ix

Story so far

Earlier from Jiangsu gdk Biotechnology

All Jiangsu gdk Biotechnology news releases